Author(s)

XiangYu Jia, YunLong Yang^*

Affiliation(s)

Department of Cardiothoracic Surgery, Affiliated Hospital of Beihua University, Jilin 132011, Jilin, China.

Corresponding Author

YunLong Yang

ABSTRACT

Antibody–drug conjugates (ADCs) are emerging as a transformative therapeutic modality for non-small cell lung cancer (NSCLC), bridging the tumor selectivity of monoclonal antibodies with the potent cytotoxicity of chemotherapy payloads. This review summarizes recent clinical progress of ADCs in NSCLC and highlights key design features that shape efficacy and safety, including antigen selection, linker chemistry, payload class, drug–antibody ratio, and the bystander effect. Particular emphasis is placed on clinically advanced targets—HER2, TROP2, HER3, and MET—as well as promising emerging antigens such as B7-H3. Across multiple studies, next-generation ADCs have shown meaningful activity in molecularly defined and treatment-refractory populations, including patients with acquired resistance to EGFR-targeted therapy and those harboring HER2 alterations. However, ADC use is constrained by distinctive toxicities, notably interstitial lung disease/pneumonitis associated with certain topoisomerase I inhibitor payloads, alongside myelosuppression and gastrointestinal adverse events. We further discuss evolving resistance mechanisms (antigen downregulation, impaired internalization, efflux transporters, and microenvironmental barriers) and outline future directions, including biomarker-guided patient selection, rational sequencing, and combination strategies with immune checkpoint inhibitors or targeted agents. Collectively, ADCs are poised to become an integral component of precision therapy for NSCLC, contingent on optimized design and proactive toxicity management.

KEYWORDS

Antibody-drug conjugates; ADCs; NSCLC

CITE THIS PAPER

XiangYu Jia, YunLong Yang. Progress and mechanisms of antibody-drug conjugates in NSCLC therapy. Journal of Pharmaceutical and Medical Research. 2026, 8(1): 28-36. DOI: https://doi.org/10.61784/jpmr3064.

REFERENCES

[1] Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med, 2025, 31(6): 1949-1957. DOI: 10.1038/s41591-025-03600-2.

[2] Li BT, Shen R, Buonocore DJ, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial. J Clin Oncol, 2018, 36(24): 2532-2537. DOI: 10.1200/JCO.2018.78.2262.

[3] Chen YJ, Shen HC, Tsai CF, et al. OBI-992, a Novel TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity in Non-Small Cell Lung Cancer. Mol Cancer Ther, 2023, 22(2): 155-167. DOI: 10.1158/1535-7163.MCT-22-0322.

[4] Odintsov I, Makarem M, Nishino M, et al. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. J Thorac Oncol, 2024, 19(5): 732-748. DOI: 10.1016/j.jtho.2023.12.019.

[5] Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol, 2024, 42(1): 47-58. DOI: 10.1200/JCO.23.02005.

[6] Hong S, Wang Q, Cheng Y, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med, 2025, 31(11): 3654-3661. DOI: 10.1038/s41591-025-03883-5.

[7] Yuan R, McGeehan A, Zhou S, et al. The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death. Mol Cancer Ther, 2025, 24(9): 1428-1441. DOI: 10.1158/1535-7163.MCT-24-0649.

[8] Yu HA, Goldberg SB, Le X, et al. A Phase I Study of U3-1402 in Patients With EGFR TKI-Resistant, EGFRm NSCLC. J Thorac Oncol, 2023, 18(9): 1535-1545. DOI: 10.1016/j.jtho.2023.05.009.

[9] Zhao S, Cheng Y, Wang Q, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med, 2025, 31(6): 1976-1986. DOI: 10.1038/s41591-025-03638-2.

[10] Li Z, Song Z, Hong W, et al. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study. Signal Transduct Target Ther, 2024, 9(1): 182. DOI: 10.1038/s41392-024-01897-y.

[11] Offin M, Feldman D, Ni A, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC: a retrospective case series. J Thorac Oncol, 2021, 16(12): e489-e490. DOI: 10.1016/j.jtho.2021.08.021.

[12] Xu S, Fang W, Wang Q, et al. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol, 2023, 19(27): 2227-2237. DOI: 10.2217/fon-2023-0181.

[13] Baldacci S, Brea EJ, Facchinetti F, et al. Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. Cancer Discov, 2025, 15(11): 2235-2250. DOI: 10.1158/2159-8290.CD-24-1515.

[14] Mok T, Janne PA, Nishio M, et al. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol, 2024, 20(15): 969-980. DOI: 10.2217/fon-2023-0602.

[15] Weng W, Meng T, Pu J, et al. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. Mol Cancer Ther, 2023, 22(9): 1013-1027. DOI: 10.1158/1535-7163.MCT-23-0198.

[16] Li Y, Wang J, He M, et al. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-expressing cancers. J Transl Med, 2024, 22(1): 362. DOI: 10.1186/s12967-024-05133-7.

[17] Schiller JH, Salgia R, Karrison T, et al. A phase II study of the antibody-drug conjugate (ADC) ABBV-399 in patients with c-Met-positive NSCLC. J Clin Oncol, 2018, 36(15_suppl): 9052. DOI: 10.1200/JCO.2018.36.15_suppl.9052.

[18] Sabari JK, Shu CA, Park K, et al. Safety and Activity of the MET Antibody-Drug Conjugate Telisotuzumab Vedotin in Patients With MET-Overexpressing NSCLC: A Phase I Trial. J Thorac Oncol, 2021, 16(6): 904-915. DOI: 10.1016/j.jtho.2021.02.018.

[19] Shu CA, Yu HA, Dang M, et al. Efficacy of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients with EGFR-Mutant, c-Met-Overexpressing Lung Cancers. J Thorac Oncol, 2022, 17(6): 901-912. DOI: 10.1016/j.jtho.2021.11.016.

[20] Kim YJ, Li W, Zhelev DV, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Cancer Immunol Immunother, 2025, 74(1): 149-162. DOI: 10.1007/s00262-024-03487-w.

[21] Li J, Zhang X, Sun Y, et al. Trastuzumab Deruxtecan in a Patient with HER2-Mutant Advanced NSCLC and Concomitant Germline BRCA2 Mutation After Failure of Osimertinib: A Case Report and Literature Review. Onco Targets Ther, 2023, 16: 249-257. DOI: 10.2147/OTT.S398554.

[22] Liu D, Jee J, Drilon A, et al. Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors. Cancer Res Commun, 2025, 5(4): 680-693. DOI: 10.1158/2767-9764.CRC-24-0620.